新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 老年性痴呆 » 武田放弃与Intra-Cellular 7.5亿美元PDE1抑制剂合作

武田放弃与Intra-Cellular 7.5亿美元PDE1抑制剂合作

来源:生物谷 2014-11-05 09:20

2014年11月5日讯 /生物谷BIOON/ --武田(Takeda)与Intra-Cellular于2011年2月签署了一笔高达7.5亿美元的协议,合作开发磷酸二酯酶1(PDE1)抑制剂用于精神分裂症患者认知功能障碍的治疗。

近日,经双方同意,武田已终止该项合作,并将ITI-214和相关的PDE1抑制剂的全部权利归还给Intra-Cellular公司,武田表示,将不再参与未来的开发和商业化活动,Intra-Cellular表示将独自继续推进PDE1抑制剂的临床开发,用于中枢神经系统、心血管及其他疾病的治疗。

根据协议条款,Intra-Cellular已重新获得先前已授权给武田的所有化合物的全球开发和商业化权利。

PDE1抑制剂是一类独特的、口服有效的实验性候选药物,目前正开发用于伴有认知障碍的精神分裂症、阿尔茨海默氏症及其他神经精神障碍失调和神经性疾病的治疗。

此外,PDE1抑制剂也有望用于注意缺陷多动障碍和帕金森氏症的治疗,有望改善与这些疾病相关的运动功能障碍。此外,PDE1抑制剂对PDE1家族成员具有高度选择性,目前未发现对其他酶、受体和离子通道有显著的脱靶效应。(生物谷Bioon.com)

英文原文:Intra-Cellular Therapies and Takeda Announce Mutual Termination of Collaboration to Develop Phosphodiesterase (PDE1) Inhibitors for CNS Disorders

NEW YORK and OSAKA, Japan, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) and Takeda Pharmaceutical Company Limited announced today that they have entered into an agreement to mutually terminate the February 2011 license agreement covering Intra-Cellular Therapies' proprietary compound ITI-214 and related PDE1 inhibitors and to return the rights for these compounds to Intra-Cellular Therapies.

Under the terms of the agreement, Intra-Cellular Therapies has regained all worldwide development and commercialization rights for the compounds previously licensed to Takeda. Takeda will be responsible for transitioning the compounds back to Intra-Cellular Therapies and will not participate in future development or commercialization activities. After transition of the program, Intra-Cellular Therapies plans to continue the clinical development of PDE1 inhibitors for the treatment of central nervous system, cardiovascular and other disorders.

"We are grateful for Takeda's substantial efforts in advancing this program into clinical development," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "This provides us with the opportunity to unify our PDE1 platform and we look forward to continuing the development of ITI-214 and our other PDE1 inhibitors."

Intra-Cellular Therapies will discuss the PDE1 program in its previously announced earnings call on Monday, November 3, 2014 at 8:30 a.m. Eastern Time. To participate in the conference call, please dial 844-835-6563 (U.S.) or 970-315-3916 (International) five to ten minutes prior to the start of the call. The participant passcode is 25568442.

About PDE1 Inhibitors

PDE1 inhibitors are unique, orally available, investigational drug candidates being developed for the treatment of cognitive impairments accompanying schizophrenia, Alzheimer's disease and other neuropsychiatric disorders and neurological diseases and may also treat patients with Attention Deficit Hyperactivity Disorder and Parkinson's disease. These compounds may also have the potential to improve motor dysfunction associated with these conditions and may also have the potential to treat patients with multiple sclerosis and other autoimmune diseases and pulmonary arterial hypertension. These compounds are very selective for the PDE1 subfamily relative to other PDE subfamilies. They have no known significant off target activities at other enzymes, receptors or ion channels.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库